RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:410 shares Right - around 230,000 of the warrants have already been exercised and brought in US$750,000. There remains 8,130,550 as of quarter end and they'll exercise at US$3.18 until Jan 2024. That is the additional $25mil that will come in if the share is above that price by then.
palinc2000 wrote: Fact check
The exercise of wsrrants remaining will add 25 millon $ to cash not 45 million$
quote=palinc2000]THX Luc ....
jfm1330 wrote: At the moment the financing led to only a 18% increase from around 80 millions share to 95 millions. Warrants will need to be execized for the 1/3 dilution to happen. Exercise price is US$3.18. So we need to remember that yes this added dilution would be bad if warrants are exercizedsince January 2024, but it would give the company an extra 45 M$. So success in oncology would come with 45 M$, more than enough to pay for three phase II studies.
quote=SPCEO1]Sorry, you are incorrect again. Sales are higher - not by a ton but still up. The stock is down by a third mostly because the ONO led to about a 1/3 increase in the number of shares.
Momo25 wrote: You are dead wrong SPECEO. Verbiage idoen't change tha facts. Question for you: If the drug sales were really boosted when Paul came in, then explain to me why the share lost a 1/3rd of its value since then?
[/quote]
[/quote]